GlycoMimetics to Present at Upcoming Healthcare Investor Conferences
November 10 2016 - 9:00AM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief
Executive Officer Rachel King will provide a company overview at
two healthcare investor conferences next week, as follows:
STIFEL 2016 HEALTHCARE CONFERENCEWHEN:
NOVEMBER 15, 2016 AT 4:30 PM ETWHERE: NEW YORK, NY, USA
JEFFERIES 2016 LONDON HEALTHCARE
CONFERENCEWHEN: NOVEMBER 17, 2016 AT 1:20 PM GMTWHERE: LONDON,
UK
To access the live webcast and subsequent archived recordings
for the presentation, please visit
the GlycoMimetics website
at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on cancer and sickle cell disease. GlycoMimetics’ most advanced
drug candidate, rivipansel, a pan-selectin antagonist, is being
developed for the treatment of vaso-occlusive crisis in sickle cell
disease and is being evaluated in a Phase 3 clinical trial being
conducted by its strategic collaborator, Pfizer. GlycoMimetics’
wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated in an ongoing Phase 1/2 clinical trial as a
potential treatment for AML and in a Phase 1 clinical trial in
multiple myeloma. GlycoMimetics has also recently initiated a
clinical trial with a third drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in
Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161110005722/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024